Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endometrial

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    330 result(s) found for: Endometrial. Displaying page 4 of 17.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-022482-95 Sponsor Protocol Number: BGOG-ov-5 Start Date*: 2012-02-07
    Sponsor Name:Belgian Gynaecological Oncolgy Group
    Full Title: BGOG-OV5:Phase II study of weekly Paclitaxel/Carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.
    Medical condition: recurrence of ovarian, fallopian tube or peritoneal carcinoma, cervical carcinoma or endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008231 Cervical cancer recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003115-34 Sponsor Protocol Number: V1 Start Date*: 2012-06-06
    Sponsor Name:Medizinische Universität Wien
    Full Title: A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles after Pelvic Lymphadenectomy in Women with Gynecologic Malignancies: a Randomized Clinical Trial
    Medical condition: endometrial cancer, cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004433-93 Sponsor Protocol Number: RIOTCSTUDY22017 Start Date*: 2018-05-01
    Sponsor Name:Nicholas Stephen Macklon, Professor, MD, PhD
    Full Title: RIOT C: REDUCING THE IMPACT OF OVARIAN STIMULATION. NOVEL APPROACHES TO LUTEAL SUPPORT IN IVF. STUDY 2.
    Medical condition: Ovarian stimulation in oocyte donation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10071130 Controlled ovarian stimulation LLT
    20.0 100000004869 10072100 Egg donor LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001576-11 Sponsor Protocol Number: 4010-03-001 Start Date*: 2019-09-10
    Sponsor Name:TESARO, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo Plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced...
    Medical condition: Recurrent or primary advanced (Stage III or IV) endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003650-24 Sponsor Protocol Number: KCP-330-005 Start Date*: 2014-01-20
    Sponsor Name:Karyopharm
    Full Title: A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 (Selinexor) in Patients with Advanced Gynaecologic Malignancies
    Medical condition: Advanced Gynaecologic Malignancies Cohort A: Ovarian carcinoma Cohort B: Endometrial carcinoma Cohort C: Cervical carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020978 10008231 Cervical cancer recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    20.0 100000020977 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002310-16 Sponsor Protocol Number: LHinPOR001 Start Date*: 2023-02-01
    Sponsor Name:UZ Brussel
    Full Title: Endometrial gene expression profiles during ovarian stimulation with recombinant human FSH with or without the addition of recombinant human LH in genuine poor responders.
    Medical condition: Infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006199-39 Sponsor Protocol Number: 310523 Start Date*: 2007-07-05
    Sponsor Name:Bayer AB, Bayer Schering Pharma
    Full Title: A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone...
    Medical condition: Women suffering from postmenopausal symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050903 Postmenopausal symptoms LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001791-36 Sponsor Protocol Number: 310781 Start Date*: 2008-01-24
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo onc...
    Medical condition: Vasomotor symptoms (hot flushes)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004467-31 Sponsor Protocol Number: DECENDO Start Date*: 2019-04-05
    Sponsor Name:
    Full Title: An exploratory study: Dendritic cells for immunotherapy of metastatic endometrial cancer patients
    Medical condition: metastatic endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016707-30 Sponsor Protocol Number: XL147-201 Start Date*: 2010-05-10
    Sponsor Name:Sanofi-aventis US Inc.
    Full Title: A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma
    Medical condition: The purpose of this study is to assess the efficacy and safety of XL147 in subjects with advanced or recurrent EC.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014747 Endometrial carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002576-16 Sponsor Protocol Number: GINECO-EN102b Start Date*: 2013-06-11
    Sponsor Name:ARCAGY
    Full Title: Phase 2 multicenter study to assess the safety and efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line therapy in patients who ...
    Medical condition: initial or recurrent metastatic endometrial cancer after first line therapy in patients who cannot undergo local surgery and/or radiotherapy.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004060-40 Sponsor Protocol Number: AGO15 Start Date*: 2008-03-13
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer
    Medical condition: primary advanced or recurrent/metastatic endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002243-42 Sponsor Protocol Number: GCT1021-01 Start Date*: 2016-10-25
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors.
    Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014742 Endometrial neoplasms malignant HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000123-28 Sponsor Protocol Number: IJB-MULTI-MIME-A-2017 Start Date*: 2018-11-14
    Sponsor Name:Institut Jules Bordet
    Full Title: Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial
    Medical condition: esophageal ADC, esophageal SCC, Cholangiocarcinoma, urothelial cancer (progressive after immunotherapy), or endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10055458 Esophageal adenocarcinoma LLT
    20.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    20.0 100000004864 10008595 Cholangiocarcinoma NOS LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10014735 Endometrial cancer NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003871-32 Sponsor Protocol Number: AL3818-US-002 Start Date*: 2021-11-11
    Sponsor Name:ADVENCHEN LABORATORIES, LLC
    Full Title: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects...
    Medical condition: Recurrent or metastatic endometrial, ovarian, fallopian tube, primary peritoneal, or cervical carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000300-26 Sponsor Protocol Number: E7080-A001-111 Start Date*: 2017-10-20
    Sponsor Name:Eisai Ltd.
    Full Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
    Medical condition: Non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal me...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 100000017553 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Completed)
    Trial results: View results
    EudraCT Number: 2018-001072-37 Sponsor Protocol Number: IRFMN-EN-7556 Start Date*: 2019-01-29
    Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri
    Full Title: AtTEnd: Atezolizumab Trial in Endometrial cancer - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/r...
    Medical condition: Newly diagnosed, histologically-confirmed stage III-IV endometrial carcinoma/carcinosarcoma with residual disease after surgery, either measurable or evaluable, and naïve to first line systemic ant...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10014772 Endometrioid adenocarcinoma recurrent LLT
    21.1 100000004864 10014776 Endometrioid adenocarcinoma stage III LLT
    21.1 100000004864 10014777 Endometrioid adenocarcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001120-54 Sponsor Protocol Number: SQ167015 Start Date*: 2016-07-25
    Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust
    Full Title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage?
    Medical condition: Recurrent miscarriage
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003203-32 Sponsor Protocol Number: 3115A1-3307-WW Start Date*: 2009-04-17
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OST...
    Medical condition: Menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027309 Menopause and related conditions HLGT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001249-15 Sponsor Protocol Number: 314-12-401 Start Date*: 2013-11-07
    Sponsor Name:Otsuka Novel Products GmbH
    Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ...
    Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041848 Squamous cell carcinoma of the cervix PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 10:20:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA